{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:42:49Z","timestamp":1793403769683,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T00:00:00Z","timestamp":1523664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.neo.2018.04.004","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T09:18:30Z","timestamp":1526375910000},"page":"632-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Phenotyping and Target Expression Profiling of CD34+\/CD38\u2212 and CD34+\/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"20","author":[{"given":"Katharina","family":"Blatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Menzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Eisenwort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Cerny-Reiterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Herndlhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Stefanzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Sadovnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hauswirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Willmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"R\u00fclicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mannhalter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junia V.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Sexl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2018.04.004_bb0005","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1200\/JCO.2005.05.047","article-title":"Molecular genetics of acute lymphoblastic leukemia","volume":"23","author":"Armstrong","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2018.04.004_bb0010","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/cncr.11664","article-title":"The biology and therapy of adult acute lymphoblastic leukemia","volume":"98","author":"Faderl","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.neo.2018.04.004_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/156800909787314057","article-title":"Emerging treatments in acute lymphoblastic leukemia","volume":"9","author":"Crazzolara","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.neo.2018.04.004_bb0020","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V91.11.3995","article-title":"Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia","volume":"91","author":"Faderl","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0025","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Gleissner","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0030","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2018.04.004_bb0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.seminhematol.2008.09.003","article-title":"Treatment of adult acute lymphoblastic leukemia","volume":"46","author":"G\u00f6kbuget","year":"2009","journal-title":"Semin Hematol"},{"key":"10.1016\/j.neo.2018.04.004_bb0040","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2141.2009.07666.x","article-title":"Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"145","author":"Gruber","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.neo.2018.04.004_bb0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/shem.2002.36927","article-title":"Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"39","author":"Hoelzer","year":"2002","journal-title":"Semin Hematol"},{"key":"10.1016\/j.neo.2018.04.004_bb0050","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0055","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0060","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","article-title":"Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia","volume":"104","author":"Towatari","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0065","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/01.cco.0000245317.82391.1b","article-title":"The changing scene of adult acute lymphoblastic leukemia","volume":"18","author":"Vitale","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.neo.2018.04.004_bb0070","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2018.04.004_bb0075","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1182\/blood.V85.11.3353.bloodjournal85113353","article-title":"Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"85","author":"Chao","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-8722-5-29","article-title":"Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia","volume":"5","author":"Chen","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.neo.2018.04.004_bb0085","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/sj.bmt.1705904","article-title":"Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia","volume":"41","author":"Fielding","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.neo.2018.04.004_bb0090","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood-2004-09-3785","article-title":"The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"105","author":"Lee","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bbmt.2011.07.019","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review","volume":"18","author":"Oliansky","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.neo.2018.04.004_bb0100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/bmt.2008.1","article-title":"Allogeneic transplantation for ALL in adults","volume":"41","author":"Stein","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.neo.2018.04.004_bb0105","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.neo.2018.04.004_bb0110","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V97.3.720","article-title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3","volume":"97","author":"Holyoake","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0115","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2008.17.5745","article-title":"Chronic myeloid leukemia stem cells","volume":"26","author":"Kavalerchik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2018.04.004_bb0120","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.molmed.2007.09.003","article-title":"Right on target: eradicating leukemic stem cells","volume":"13","author":"Krause","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.neo.2018.04.004_bb0125","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.neo.2018.04.004_bb0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/leu.2008.246","article-title":"Targeting the leukemic stem cell: the Holy Grail of leukemia therapy","volume":"23","author":"Misaghian","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2018.04.004_bb0135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/156800911793743655","article-title":"Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept","volume":"11","author":"Valent","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.neo.2018.04.004_bb0140","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.leu.2403649","article-title":"Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease","volume":"19","author":"Eisterer","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2018.04.004_bb0145","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0150","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood.V95.3.1007.003k35_1007_1013","article-title":"A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia","volume":"95","author":"Cobaleda","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0155","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2004-03-0901","article-title":"Characterization of acute lymphoblastic leukemia progenitor cells","volume":"104","author":"Cox","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0160","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2008.83","article-title":"CD34\u202f+\u202fCD38\u202f+\u202fCD19+ as well as CD34\u202f+\u202fCD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL","volume":"22","author":"Kong","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2018.04.004_bb0165","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ccr.2008.05.015","article-title":"In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties","volume":"14","author":"le Viseur","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2018.04.004_bb0170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10428190500272507","article-title":"Detection of molecular targets on the surface of CD34+\/CD38-- stem cells in various myeloid malignancies","volume":"47","author":"Florian","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.neo.2018.04.004_bb0175","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3324\/haematol.2010.035006","article-title":"CD34(+)\/CD38(\u2212) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab\/ozogamicin","volume":"97","author":"Herrmann","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.neo.2018.04.004_bb0180","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.18632\/oncotarget.1805","article-title":"Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia","volume":"5","author":"Cerny-Reiterer","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2018.04.004_bb0185","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-13-2811","article-title":"Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML","volume":"20","author":"Blatt","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2018.04.004_bb0190","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/eci.12368","article-title":"DPPIV (CD26) as a novel stem cell marker in Ph\u202f+\u202fchronic myeloid leukaemia","volume":"44","author":"Valent","year":"2014","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.neo.2018.04.004_bb0195","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/sj.leu.2400836","volume":"11","author":"Paietta","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2018.04.004_bb0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood.V96.1.9","article-title":"Fates of human B-cell precursors","volume":"96","author":"LeBien","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0205","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0210","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"J\u00e4r\u00e5s","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2018.04.004_bb0215","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2017.36","article-title":"Differential signaling networks of Bcr\u2013Abl p210 and p190 kinases in leukemia cells defined by functional proteomics","volume":"31","author":"Reckel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2018.04.004_bb0220","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/leu.2017.61","article-title":"Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis","volume":"31","author":"Cutler","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2018.04.004_bb0225","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-15-0767","article-title":"Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph\u202f+\u202fCML","volume":"22","author":"Sadovnik","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2018.04.004_bb0230","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2012-02-414425","article-title":"CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900","volume":"120","author":"G\u00f6nen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.neo.2018.04.004_bb0235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1517\/14712598.2.1.97","article-title":"Rituximab: clinical development and future directions","volume":"2","author":"Cheson","year":"2002","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.neo.2018.04.004_bb0240","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3109\/10428191003717746","article-title":"The future of CD20 monoclonal antibody therapy in B-cell malignancies","volume":"51","author":"Czuczman","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.neo.2018.04.004_bb0245","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2018.04.004_bb0250","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/CCO.0000000000000009","article-title":"Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia","volume":"25","author":"Hoelzer","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.neo.2018.04.004_bb0255","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.blre.2011.08.001","article-title":"Chemoimmunotherapy in acute lymphoblastic leukemia","volume":"26","author":"Hoelzer","year":"2012","journal-title":"Blood Rev"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558618300885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558618300885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T22:13:48Z","timestamp":1571350428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558618300885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1476558618300885"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2018.04.004","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenotyping and Target Expression Profiling of CD34+\/CD38\u2212 and CD34+\/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2018.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of SOCIETY. CC BY-NC-ND 4.0","name":"copyright","label":"Copyright"}]}}